The authors wish to thank Prolucid Technologies for its development and deployment of the physician platform.
Data availabilityAll raw data collected from the study cannot be made publicly available given limitations from the informed consent form and ethics board approval. The raw data can be shared by the corresponding author without cost for unrestricted non-commercial purposes; however, the use will be subject to approval from the Research Ethics Board of the McGill University Health Centre. After approval, reasonable efforts will be made for the data to be shared within 3 months.
FundingThis study was funded by the Canada Research Chairs Program awarded to AH. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Authors’ relationships and activitiesAH received consultancy fees from Eli Lilly and Abbott, research support from Dexcom, Tandem and Beta Bionics, and speaker fees from SiBionics. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Contribution statementAK and AH conceptualised the study and designed the physician platform. AK led the study conduct. JR and AEF developed the physician platform graphs; AK and JR performed platform testing. J-FY and SJM performed pre-study platform pilot testing. MAT, NG, LL, M-RP, J-FY, SJM, SSW, SM, VT, TP, RB, PK and IGF completed assessments for part A. MAT, NG, LL, M-RP, J-FY, SJM, SM, SSW, VT, TP, RB and PK completed data assessments for part B. MAT, NG, LL, M-RP, SSW, SM, VT, TP and RB completed assessments for part C. AN processed the data and created the boxplots. LEL conducted the statistical analyses. AK and AH interpreted the results. AK drafted and revised the manuscript under the supervision of AH; all authors reviewed and approved the final manuscript. AH is the guarantor of this work and accepts full responsibility for the work and/or the conduct of the study, had access to the data and made the decision to publish.
Comments (0)